---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-097860"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:36:22.158505+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical Q3 revenue falls to $56K; FDA OKs pivotal trial for Acclaim CI

## Summary
- Net revenues $56K for Q3 2024, down 30% from $80K in Q3 2023; nine-month revenues $183K, down 17%.
- Cash and cash equivalents $4.4M as of Sep 30, 2024, with R&D expenses up 47% to $2.8M due to clinical prep for Acclaim CI.
- FDA approved initiation of pivotal clinical study for fully implanted Acclaim Cochlear Implant (investigational, Breakthrough Device).
- AMA CPT Editorial Panel approved Category III CPT codes for totally implantable middle ear hearing devices (support for Esteem FI-AMEI reimbursement).
- Bipartisan House and Senate bills introduced to change CMS classification for fully implanted middle ear hearing devices for Medicare coverage.

## SEC filing metadata
- accession: 0001213900-24-097860
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390024097860/0001213900-24-097860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390024097860/ea0221085-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-097860
- JSON: https://secwatch.observer/filing/0001213900-24-097860.json
- Plain text: https://secwatch.observer/filing/0001213900-24-097860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.